Dianthus Therapeutics (DNTH) net assets (shareholders' equity)

Net assets · fiscal 2025
$493.40M

Dianthus Therapeutics (DNTH) had net assets of $493.40M at the end of fiscal 2025 (December 31, 2025). That is 40.0% higher than the $352.48M of fiscal 2024. Figures as of 19 Nov 2026, 03:14 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$493.40M
Change on fiscal 2024
+40.0%
Growth, 5 years
+27.9% a year
Highest on record
$493.40Mfiscal 2025
Lowest on record
-$42.12Mfiscal 2017
Fiscal years on record
102016–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Dianthus Therapeutics net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets grew at a compound 27.9% a year. Across the 10 fiscal years on record (2016–2025), the highest was $493.40M in fiscal 2025 and the lowest -$42.12M in fiscal 2017.

History · 10 fiscal years

Net assets by fiscal year

Dianthus Therapeutics net assets (shareholders' equity), year by year

Dianthus Therapeutics (DNTH) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$493.40M 40.0% up
2024$352.48M 108.7% up
2023$168.87M 129.3% up
2022$73.66M—
2021-$17.25M 112.0% down
2020$143.91M 1.9% up
2019$141.19M 3.1% down
2018$145.65M—
2017-$42.12M—
2016-$8.87M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of Dianthus Therapeutics and comparable companies
CompanyNet assetsFiscal year
LivaNova LIVN$1.20B2025
Ionis Pharmaceuticals IONS$489.09M2025
Dianthus Therapeutics DNTH$493.40M2025
MiniMed Group MMED$3.61B2026
Adaptive Biotechnologies ADPT$218.79M2025
Heartflow HTFL$300.65M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on DNTH

Dianthus Therapeutics, figure by figure

Dianthus Therapeutics (DNTH) overview: price, valuation and scorecardAll health care companies by market value

Dianthus Therapeutics net assets (shareholders' equity): questions and answers

What are Dianthus Therapeutics's net assets?

Dianthus Therapeutics (DNTH) had net assets of $493.40M at the end of fiscal 2025 (December 31, 2025). That is 40.0% higher than the $352.48M of fiscal 2024.

What is the growth rate of Dianthus Therapeutics's net assets?

Over the five fiscal years to 2025 net assets grew at a compound 27.9% a year.

What are the highest and lowest net assets figures on record for Dianthus Therapeutics?

Across the 10 fiscal years on record (2016–2025), the highest was $493.40M in fiscal 2025 and the lowest -$42.12M in fiscal 2017.

How is Dianthus Therapeutics's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Dianthus Therapeutics it is on record here for 10 fiscal years, 2016 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Dianthus Therapeutics (DNTH) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/DNTH/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.